Reglagene Inc. has prepared and tested compounds reported to be useful for the treatment of cancer, familial Mediterranean fever, gout and nail fungal infection.
Bioatla Inc. and Context Therapeutics Inc. have entered into an agreement under which Context has obtained from Bioatla an exclusive, worldwide license to develop, manufacture and commercialize BA-3362, Bioatla’s Nectin-4 x CD3 T-cell engaging (TCE) bispecific antibody.
The FDA has cleared an IND application for a phase I/II study of KSQ-004EX, KSQ Therapeutics Inc.’s second engineered tumor-infiltrating lymphocyte (eTIL) program. KSQ-004EX consists of TIL in which the genes encoding SOCS1 and Regnase-1 are inactivated using CRISPR/Cas9 gene editing.
Ribometrix Inc. recently discussed the discovery and preclinical evaluation of a novel potent and selective eukaryotic translation initiation factor 4E (eiF4E) inhibitor, RBX-6610, being developed for the treatment of KRAS-mutant non-small-cell lung cancer (NSCLC).
Work at Innovstone Therapeutics Ltd. has led to the identification of new dihydrothienopyrimidine derivatives acting as phosphodiesterase PDE4B inhibitors.
A Hitgen Ltd. patent details aromatic-ring compounds acting as E3 ubiquitin-protein ligase (TRIM21) ligands reported to be useful for the treatment of cancer.
Zydus Lifesciences Ltd. has patented new compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors.
Innate Pharma SA has obtained IND clearance from the FDA for IPH-4502, its novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) conjugated to exatecan targeting Nectin-4 in solid tumors. In nonclinical models, IPH-45 was well tolerated and showed antitumor efficacy in vitro and in vivo.
Gastric cancer (GC) is among the most malignant tumors in terms of incidence and mortality. Early diagnosis can improve the survival rate of patients, but there is a lack of effective biomarkers for the diagnosis and prognosis of GC. Zinc finger protein 1 homologue (ZFP1) plays an important role in transcriptional regulation during embryonic development. Its homologue, MLLT10, had been found to promote carcinogenesis in leukemia and colon cancer, but limited knowledge exists on the role of ZFP1 in cancer.
RSS
